Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL506231 | 0.81 | ALDH1A1 (0.35) | ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL7648836 | 0.77 | ALDH1A1 (0.46) | ALDH1A1MAPTL3MBTL1MAOAGAA | |
| SCHEMBL18871416 | 0.77 | ALDH1A1 (0.46) | ALDH1A1MAPTL3MBTL1MAOAGAA | |
| SCHEMBL581954 | 0.77 | ALDH1A1 (0.46) | ALDH1A1MAPTL3MBTL1MAOAGAA | |
| SCHEMBL2324941 | 0.76 | — | — | |
| SCHEMBL18871435 | 0.73 | ALDH1A1 (0.43) | ALDH1A1MAPTL3MBTL1MAOAGAA | |
| SCHEMBL2575397 | 0.73 | ALDH1A1 (0.47) | ALDH1A1MAPTL3MBTL1MAOAGAA | |
| SCHEMBL7617454 | 0.72 | ALDH1A1 (0.42) | ALDH1A1MAPTL3MBTL1MAOAGAA | |
| SCHEMBL13167192 | 0.71 | — | — | |
| SCHEMBL4928133 | 0.69 | ALDH1A1 (0.40) | ALDH1A1MAPTL3MBTL1MAOAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1765 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4395831-A1 | COMPOSITIONS AND METHODS FOR SKIPPING EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY | Entrada Therapeutics, Inc. (US) | 2024-07-10 | — | — | EP | claimed |
| EP-4395829-A1 | COMPOUNDS AND METHODS FOR SKIPPING EXON 44 IN DUCHENNE MUSCULAR DYSTROPHY | Entrada Therapeutics, Inc. (US) | 2024-07-10 | — | — | EP | claimed |
| CN-118284434-A | Compositions and methods for skipping exon 45 in duchenne muscular dystrophy | 恩特拉达治疗学股份有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-118215504-A | Compounds and methods for skipping exon 44 in duchenne muscular dystrophy | 恩特拉达治疗学股份有限公司 | 2024-06-18 | — | — | CN | claimed |
| EP-4359006-A1 | ANTISENSE COMPOUNDS AND METHODS FOR TARGETING CUG REPEATS | Entrada Therapeutics, Inc. (US) | 2024-05-01 | — | — | EP | claimed |
| CN-117957022-A | Antisense compounds and methods for targeting CUG repeats | 安卓达治疗股份有限公司 | 2024-04-30 | — | — | CN | claimed |
| CN-117915957-A | Compositions and methods for modulating mRNA splicing | 恩特拉达治疗学股份有限公司 | 2024-04-19 | — | — | CN | claimed |
| CN-117897176-A | Compositions and methods for modulating tissue distribution of intracellular therapeutic agents | 恩特拉达治疗学股份有限公司 | 2024-04-16 | — | — | CN | claimed |
| EP-4337264-A1 | COMPOSITIONS AND METHODS FOR MODULATING TISSUE DISTRIBUTION OF INTRACELLULAR THERAPEUTICS | Entrada Therapeutics, Inc. (US) | 2024-03-20 | — | — | EP | claimed |
| EP-4337263-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERFERON REGULATORY FACTOR-5 (IRF-5) ACTIVITY | Entrada Therapeutics, Inc. (US) | 2024-03-20 | — | — | EP | claimed |
| US-6930085-B2 | G-type peptides to ameliorate atherosclerosis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-08-16 | — | — | US | claimed |
| US-20050164950-A1 | Orally administered small peptides synergize statin activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2005-07-28 | — | — | US | claimed |
| US-6869932-B2 | Site-specific preparation of polyethlene glycol-GRF conjugates | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-03-22 | — | — | US | claimed |
| US-20040266671-A1 | Orally administered peptides synergize statin activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-12-30 | — | — | US | claimed |
| US-20040254120-A1 | Orally administered small peptides synergize statin activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-12-16 | — | — | US | claimed |
| US-20040248815-A1 | Substituted amino acids as erythropoietin mimetics | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2004-12-09 | — | — | US | claimed |
| US-6664230-B1 | Amino acid sequence 5 having at least one dextro residue; retains biological activity; elevated serum halflife | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-12-16 | — | — | US | claimed |
| US-20020016350-A1 | Substituted amino acids as erythropoietin mimetics | CONNOLLY PETER J (US) | 2002-02-07 | — | — | US | claimed |
| US-6310078-B1 | MODULATING ERYTHROPOIETIN RECEPTOR, TREATING DISEASE OR CONDITION MEDIATED BY SAID RECEPTOR | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-10-30 | — | — | US | claimed |
| US-6306911-B1 | ENZYME INHIBITORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-10-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016350-A1 | Substituted amino acids as erythropoietin mimetics | EPOR, EDNRA, FLT1 | ALDH1A1 903/4885MAPT 4161/4885L3MBTL1 3681/4885 |
| US-20040248815-A1 | Substituted amino acids as erythropoietin mimetics | EPOR, EDNRA, FLT1 | ALDH1A1 903/4885MAPT 4161/4885L3MBTL1 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.